SKLB-329

N/A

Report date: 2022/06/10 17:19:15

NME

Base Information

Drug NameSKLB-329

Drug Alias NameSKLB-329

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonistsVascular endothelial growth factor receptor 3 antagonists +[5]

TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 2Vascular endothelial growth factor receptor 3 +[5]

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesSichuan University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSichuan University

Active IndicationsN/A

Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A